Allscripts (NASDAQ: MDRX) reported Q1 EPS of $0.19, $0.04 better than the analyst estimate of $0.15. Revenue for the quarter came in at $368.4 million versus the consensus estimate of $368.66 million.

“Entering 2021, Allscripts continued to benefit from our strategic investments in distinctive, relevant and comprehensive solutions for our clients across the provider, payer and life sciences end markets. While regional uncertainty remains regarding the trajectory of COVID-19, we are optimistic as the pace of vaccinations increases, patient volumes recover, and we see expanded demand for closed loop connectivity to real world data,” said Paul M. Black, Allscripts Chief Executive Officer. “We were pleased with our strong first quarter results, as we gained from a more robust selling environment and a determined discipline around our cost structure. Looking forward expect a steady, purposeful focus on improving margins, generating free cash flow and serving our clients as they lead their organizations through the pandemic.”

GUIDANCE:

Allscripts sees FY2021 revenue of $1.5 billion, versus the consensus of $1.5 billion.

Allscripts is affirming its prior annual outlook and currently expects to achieve:

• Revenue of $1.5 billion
• Adjusted EBITDA between $240 million and $260 million
• Free cash flow between $90 million and $100 million

For earnings history and earnings-related data on Allscripts (MDRX) click here.